Emmaus Life Sciences (EMMA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Emmaus Life Sciences is a biopharmaceutical company with a mission to develop and commercialize innovative therapies, initially for rare diseases. Its primary achievement is the 2017 FDA approval of Endari (L-glutamine oral powder) for sickle cell disease, establishing a commercial foundation. The company's strategy involves expanding Endari's global footprint, exploring its glutamine-based science in new indications like diverticulosis, and developing a novel cell sheet engineering platform. Recent leadership changes and a focus on financial improvement signal a period of strategic transition.

HematologyGastroenterology

Technology Platform

Centered on the therapeutic application of pharmaceutical-grade L-glutamine to modulate oxidative stress and metabolism; also exploring a cell sheet engineering platform for regenerative medicine.

Opportunities

Significant opportunity exists in expanding Endari's global access, particularly in international markets like the GCC and India where sickle cell disease prevalence is high.

The strategic pivot to develop L-glutamine for diverticulosis targets a vast, underserved patient population with no approved pharmacologic treatments, representing a potential multi-billion dollar market expansion.

Risk Factors

The company faces extreme financial vulnerability with a near-zero market valuation and a history of delayed filings, creating liquidity risk.

It is overwhelmingly reliant on a single commercial product, Endari, in an increasingly competitive sickle cell disease landscape.

The strategic shift to diverticulosis carries high execution risk given limited resources and unproven expertise in gastroenterology.

Competitive Landscape

In sickle cell disease, Endari faces intense competition from novel disease-modifying drugs (voxelotor, crizanlizumab) and curative gene therapies (Casgevy, Lyfgenia), which threaten to marginalize it as a supportive care option. In the nascent diverticulosis pharmaceutical market, success would require demonstrating clear efficacy over current standard of care (diet, antibiotics, surgery) in a large, untapped patient population.

More companies in Rare & Orphan Diseases →More companies in United States →